<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36240025</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2373-9878</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>ACS biomaterials science &amp; engineering</Title><ISOAbbreviation>ACS Biomater Sci Eng</ISOAbbreviation></Journal><ArticleTitle>Design of Mesoporous Silica Nanoparticles for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with a Therapeutic Cocktail Based on Leptin and Pioglitazone.</ArticleTitle><Pagination><StartPage>4838</StartPage><EndPage>4849</EndPage><MedlinePgn>4838-4849</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsbiomaterials.2c00865</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devasting neurodegenerative disease with no cure to date. Therapeutic agents used to treat ALS are very limited, although combined therapies may offer a more effective treatment strategy. Herein, we have studied the potential of nanomedicine to prepare a single platform based on mesoporous silica nanoparticles (MSNs) for the treatment of an ALS animal model with a cocktail of agents such as leptin (neuroprotective) and pioglitazone (anti-inflammatory), which have already demonstrated promising therapeutic ability in other neurodegenerative diseases. Our goal is to study the potential of functionalized mesoporous materials as therapeutic agents against ALS using MSNs as nanocarriers for the proposed drug cocktail leptin/pioglitazone (<b>MSN-LEP-PIO</b>). The nanostructured materials have been characterized by different techniques, which confirmed the incorporation of both agents in the nanosystem. Subsequently, the effect, <i>in vivo</i>, of the proposed drug cocktail, <b>MSN-LEP-PIO</b>, was used in the murine model of TDP-43 proteinopathy (TDP-43<sup>A315T</sup> mice). Body weight loss was studied, and using the rotarod test, motor performance was assessed, observing a continuous reduction in body weight and motor coordination in TDP-43<sup>A315T</sup> mice and wild-type (WT) mice. Nevertheless, the disease progression was slower and showed significant improvements in motor performance, indicating that TDP-43<sup>A315T</sup> mice treated with <b>MSN-LEP-PIO</b> seem to have less energy demand in the late stage of the symptoms of ALS. Collectively, these results seem to indicate the efficiency of the systems <i>in vivo</i> and the usefulness of their use in neurodegenerative models, including ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#xed;az-Garc&#xed;a</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>COMET-NANO Group, Departamento de Biolog&#xed;a y Geolog&#xed;a, F&#xed;sica y Qu&#xed;mica Inorg&#xe1;nica, E.S.C.E.T., Universidad Rey Juan Carlos, Calle Tulip&#xe1;n s/n, E-28933 M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer-Donato</LastName><ForeName>&#xc1;gueda</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Neurometabolism Group, Research Unit of the National Hospital of Paraplegics (UDI-HNP), Finca La Peraleda s/n, 45071 Toledo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;ndez-Arriaga</LastName><ForeName>Jos&#xe9; M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>COMET-NANO Group, Departamento de Biolog&#xed;a y Geolog&#xed;a, F&#xed;sica y Qu&#xed;mica Inorg&#xe1;nica, E.S.C.E.T., Universidad Rey Juan Carlos, Calle Tulip&#xe1;n s/n, E-28933 M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrera-Pinto</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurometabolism Group, Research Unit of the National Hospital of Paraplegics (UDI-HNP), Finca La Peraleda s/n, 45071 Toledo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-S&#xe1;nchez</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>COMET-NANO Group, Departamento de Biolog&#xed;a y Geolog&#xed;a, F&#xed;sica y Qu&#xed;mica Inorg&#xe1;nica, E.S.C.E.T., Universidad Rey Juan Carlos, Calle Tulip&#xe1;n s/n, E-28933 M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prashar</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>COMET-NANO Group, Departamento de Biolog&#xed;a y Geolog&#xed;a, F&#xed;sica y Qu&#xed;mica Inorg&#xe1;nica, E.S.C.E.T., Universidad Rey Juan Carlos, Calle Tulip&#xe1;n s/n, E-28933 M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Martos</LastName><ForeName>Carmen M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Neurometabolism Group, Research Unit of the National Hospital of Paraplegics (UDI-HNP), Finca La Peraleda s/n, 45071 Toledo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wicking Dementia Research and Education Centre, College of Health and Medicine, University of Tasmania, Hobart, Tasmania 7005, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Ruiz</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9538-8359</Identifier><AffiliationInfo><Affiliation>COMET-NANO Group, Departamento de Biolog&#xed;a y Geolog&#xed;a, F&#xed;sica y Qu&#xed;mica Inorg&#xe1;nica, E.S.C.E.T., Universidad Rey Juan Carlos, Calle Tulip&#xe1;n s/n, E-28933 M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Biomater Sci Eng</MedlineTA><NlmUniqueID>101654670</NlmUniqueID><ISSNLinking>2373-9878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X4OV71U42S</RegistryNumber><NameOfSubstance UI="D000077205">Pioglitazone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020738">Leptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>7631-86-9</RegistryNumber><NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077205" MajorTopicYN="N">Pioglitazone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020738" MajorTopicYN="N">Leptin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012822" MajorTopicYN="N">Silicon Dioxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">drug delivery</Keyword><Keyword MajorTopicYN="N">leptin</Keyword><Keyword MajorTopicYN="N">mesoporous silica nanoparticles</Keyword><Keyword MajorTopicYN="N">pioglitazone</Keyword></KeywordList><CoiStatement>The
authors declare no
competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36240025</ArticleId><ArticleId IdType="pmc">PMC9667463</ArticleId><ArticleId IdType="doi">10.1021/acsbiomaterials.2c00865</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nanostructured Materials and Their Applications; Logothetidis S., Ed.; Springer-Verlag: Berlin, 2012.</Citation></Reference><Reference><Citation>Nanotechnology: Synthesis to Applications; Roy S.; Ghosh C. K.; Sarkar C. K., Eds.; CRC Press: Boca Raton, 2020.</Citation></Reference><Reference><Citation>Khan H. A.; Sakharkar M. K.; Nayak A.; Kishore U.; Khan A.. Nanoparticles for Biomedical Applications: An Overview. In Nanobiomaterials; Narayan R., Ed.; Woodhead Publishing, 2018; Chapter 14, pp 357&#x2013;384.</Citation></Reference><Reference><Citation>Shi J.; Kantoff P. W.; Wooster R.; Farokhzad O. C. Cancer Nanomedicine: Progress, Challenges and Opportunities. Nat. Rev. Cancer 2017, 17, 20&#x2013;37. 10.1038/nrc.2016.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2016.108</ArticleId><ArticleId IdType="pmc">PMC5575742</ArticleId><ArticleId IdType="pubmed">27834398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai A.; Noor S.; Ahmad S. I.; Alajmi M. F.; Hussain A.; Abbas H.; Hasan G. M. Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics. Medicina 2021, 57, 91.10.3390/medicina57020091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57020091</ArticleId><ArticleId IdType="pmc">PMC7909769</ArticleId><ArticleId IdType="pubmed">33494239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wani W. A.; Prashar S.; Shreaz S.; G&#xf3;mez-Ruiz S. Nanostructured Materials Functionalized with Metal Complexes: In Search of Alternatives for Administering Anticancer Metallodrugs. Coord. Chem. Rev. 2016, 312, 67&#x2013;98. 10.1016/j.ccr.2016.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2016.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandarana M.; Curtis A.; Hoskins C. The Use of Nanotechnology in Cardiovascular Disease. Appl. Nanosci. 2018, 8, 1607&#x2013;1619. 10.1007/s13204-018-0856-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13204-018-0856-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P.; Evelyn G.; Amrita S.; Sumit K.; Khadija R.; Hitendra S. C.; Rahul D. J. Nanoparticle Based Treatment for Cardiovascular Diseases. Cardiovasc. Hematol. Disord. &#x2013; Drug Targets 2019, 19, 33&#x2013;44. 10.2174/1871529X18666180508113253.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871529X18666180508113253</ArticleId><ArticleId IdType="pubmed">29737265</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N.-Y.; Ko W.-C.; Hsueh P.-R. Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms. Front. Pharmacol. 2019, 10, 1153.10.3389/fphar.2019.01153.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01153</ArticleId><ArticleId IdType="pmc">PMC6787836</ArticleId><ArticleId IdType="pubmed">31636564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolnik B. S.; Gonz&#xe1;lez-Fern&#xe1;ndez &#xc1;.; Sadrieh N.; Dobrovolskaia M. A. Nanoparticles and the Immune System. Endocrinology 2010, 151, 458&#x2013;465. 10.1210/en.2009-1082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2009-1082</ArticleId><ArticleId IdType="pmc">PMC2817614</ArticleId><ArticleId IdType="pubmed">20016026</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S.-Y.; Liu Y.; Xu C.-F.; Shen S.; Sun R.; Du X.-J.; Xia J.-X.; Zhu Y.-H.; Wang J. Restoring Anti-Tumor Functions of T Cells via Nanoparticle-Mediated Immune Checkpoint Modulation. J. Controlled Release 2016, 231, 17&#x2013;28. 10.1016/j.jconrel.2016.01.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.01.044</ArticleId><ArticleId IdType="pubmed">26829099</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavarpour-Bali H.; Ghasemi-Kasman M.; Pirzadeh M. Curcumin-Loaded Nanoparticles: A Novel Therapeutic Strategy in Treatment of Central Nervous System Disorders. Int. J. Nanomed. 2019, 14, 4449&#x2013;4460. 10.2147/IJN.S208332.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S208332</ArticleId><ArticleId IdType="pmc">PMC6592058</ArticleId><ArticleId IdType="pubmed">31417253</ArticleId></ArticleIdList></Reference><Reference><Citation>Babazadeh A.; Mohammadi Vahed F.; Jafari S. M. Nanocarrier-Mediated Brain Delivery of Bioactives for Treatment/Prevention of Neurodegenerative Diseases. J. Controlled Release 2020, 321, 211&#x2013;221. 10.1016/j.jconrel.2020.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.02.015</ArticleId><ArticleId IdType="pubmed">32035189</ArticleId></ArticleIdList></Reference><Reference><Citation>Persano F.; Batasheva S.; Fakhrullina G.; Gigli G.; Leporatti S.; Fakhrullin R. Recent Advances in the Design of Inorganic and Nano-Clay Particles for the Treatment of Brain Disorders. J. Mater. Chem. B 2021, 9, 2756&#x2013;2784. 10.1039/D0TB02957B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0TB02957B</ArticleId><ArticleId IdType="pubmed">33596293</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T. T.; Vo T. K.; Tran N.-M.-A.; Nguyen M. K.; Van Vo T.; Van Vo G. Nanotechnology-Based Drug Delivery for Central Nervous System Disorders. Biomed. Pharmacother. 2021, 143, 11211710.1016/j.biopha.2021.112117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112117</ArticleId><ArticleId IdType="pubmed">34479020</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia R. Cellular and Molecular Mechanisms of Motor Neuron Death in Amyotrophic Lateral Sclerosis: A Perspective. Front. Cell. Neurosci. 2014, 8, 241.10.3389/fncel.2014.00241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00241</ArticleId><ArticleId IdType="pmc">PMC4132292</ArticleId><ArticleId IdType="pubmed">25177274</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipi T.; Hermanova Z.; Tureckova J.; Vanatko O.; Anderova M. Glial Cells&#x2014;The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 2020, 9, 261.10.3390/jcm9010261.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010261</ArticleId><ArticleId IdType="pmc">PMC7020059</ArticleId><ArticleId IdType="pubmed">31963681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz B.; Reimann J.; Dumitrescu-Ozimek L.; Kappes-Horn K.; Landreth G. E.; Sch&#xfc;rmann B.; Zimmer A.; Heneka M. T. The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice. J. Neurosci. 2005, 25, 7805&#x2013;7812. 10.1523/JNEUROSCI.2038-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2038-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725264</ArticleId><ArticleId IdType="pubmed">16120782</ArticleId></ArticleIdList></Reference><Reference><Citation>Willson T. M.; Brown P. J.; Sternbach D. D.; Henke B. R. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527&#x2013;550. 10.1021/jm990554g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm990554g</ArticleId><ArticleId IdType="pubmed">10691680</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens T. W.; Basinski M.; Bristow P. K.; Bue-Valleskey J. M.; Burgett S. G.; Craft L.; Hale J.; Hoffmann J.; Hsiung H. M.; Kriauciunas A.; et al. The Role of Neuropeptide Y in the Antiobesity Action of the Obese Gene Product. Nature 1995, 377, 530&#x2013;532. 10.1038/377530a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/377530a0</ArticleId><ArticleId IdType="pubmed">7566151</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.; Proenca R.; Maffei M.; Barone M.; Leopold L.; Friedman J. M. Positional Cloning of the Mouse Obese Gene and Its Human Homologue. Nature 1994, 372, 425&#x2013;432. 10.1038/372425a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/372425a0</ArticleId><ArticleId IdType="pubmed">7984236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton K.; Harvey J. The Neuronal Actions of Leptin and the Implications for Treating Alzheimer&#x2019;s Disease. Pharmaceuticals 2021, 14, 52.10.3390/ph14010052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14010052</ArticleId><ArticleId IdType="pmc">PMC7827292</ArticleId><ArticleId IdType="pubmed">33440796</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.-Q.; Tian Q.; Li D.; He S.-Q.; Hu M.; Liu S.-Y.; Zou W.; Chen Y.-J.; Zhang P.; Tang X.-Q. Leptin Mediates Protection of Hydrogen Sulfide against 6-Hydroxydopamine-Induced Parkinson&#x2019;s Disease: Involving Enhancement in Warburg Effect. Neurochem. Int. 2020, 135, 10469210.1016/j.neuint.2020.104692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2020.104692</ArticleId><ArticleId IdType="pubmed">32032636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S. T.; Steyn F. J.; Huang L.; Mantovani S.; Pfluger C. M. M.; Woodruff T. M.; O&#x2019;Sullivan J. D.; Henderson R. D.; McCombe P. A. Altered Expression of Metabolic Proteins and Adipokines in Patients with Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2015, 357, 22&#x2013;27. 10.1016/j.jns.2015.06.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.053</ArticleId><ArticleId IdType="pubmed">26198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G.; Peter R. S.; Rosenbohm A.; Koenig W.; Dupuis L.; Rothenbacher D.; Ludolph A. C. Adipokines, C-Reactive Protein and Amyotrophic Lateral Sclerosis &#x2013; Results from a Population- Based ALS Registry in Germany. Sci. Rep. 2017, 7, 437410.1038/s41598-017-04706-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R. M.; Phan K.; Highton-Williamson E.; Strikwerda-Brown C.; Caga J.; Ramsey E.; Zoing M.; Devenney E.; Kim W. S.; Hodges J. R.; Piguet O.; Halliday G. M.; Kiernan M. C. Eating Peptides: Biomarkers of Neurodegeneration in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Ann. Clin. Transl. Neurol. 2019, 6, 486&#x2013;495. 10.1002/acn3.721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.721</ArticleId><ArticleId IdType="pmc">PMC6414477</ArticleId><ArticleId IdType="pubmed">30911572</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin A. S.; Lee V. M.-Y.; Trojanowski J. Q. TAR DNA-Binding Protein 43 in Neurodegenerative Disease. Nat. Rev. Neurol. 2010, 6, 211&#x2013;220. 10.1038/nrneurol.2010.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.18</ArticleId><ArticleId IdType="pmc">PMC2892118</ArticleId><ArticleId IdType="pubmed">20234357</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.; Kelsey A. H.; Graeme M.; Rachel A. K. A.; Justin D.; James C. V.; Carmen M. F.-M.; Anna E. K. Enhanced Anti-Amyloid Effect of Combined Leptin and Pioglitazone in APP/PS1 Transgenic Mice. Curr. Alzheimer Res. 2020, 17, 1294&#x2013;1301. 10.2174/1567205018666210218163857.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205018666210218163857</ArticleId><ArticleId IdType="pubmed">33602093</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Martos C. M.; Atkinson R. A. K.; Chuah M. I.; King A. E.; Vickers J. C. Combination Treatment with Leptin and Pioglitazone in a Mouse Model of Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Dementia: Transl. Res. Clin. Interventions 2017, 3, 92&#x2013;106. 10.1016/j.trci.2016.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2016.11.002</ArticleId><ArticleId IdType="pmc">PMC5651376</ArticleId><ArticleId IdType="pubmed">29067321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G. Y.; Rayner S. L.; Chung R.; Shi B. Y.; Liang X. J. Advances in Nanotechnology-Based Strategies for the Treatments of Amyotrophic Lateral Sclerosis. Mater. Today Bio 2020, 6, 10005510.1016/j.mtbio.2020.100055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2020.100055</ArticleId><ArticleId IdType="pmc">PMC7280770</ArticleId><ArticleId IdType="pubmed">32529183</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano M.; Vallet-Reg&#xed; M. Mesoporous Silica Nanoparticles in Nanomedicine Applications. J. Mater. Sci.: Mater. Med. 2018, 29, 65.10.1007/s10856-018-6069-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10856-018-6069-x</ArticleId><ArticleId IdType="pubmed">29737405</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra J. K.; Das G.; Fraceto L. F.; Campos E. V. R.; Rodriguez-Torres M. D. P.; Acosta-Torres L. S.; Diaz-Torres L. A.; Grillo R.; Swamy M. K.; Sharma S.; Habtemariam S.; Shin H.-S. Nano Based Drug Delivery Systems: Recent Developments and Future Prospects. J. Nanobiotechnol. 2018, 16, 71.10.1186/s12951-018-0392-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-018-0392-8</ArticleId><ArticleId IdType="pmc">PMC6145203</ArticleId><ArticleId IdType="pubmed">30231877</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet-Reg&#xed; M.; Colilla M.; Izquierdo-Barba I.; Manzano M. Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights. Molecules 2018, 23, 47.10.3390/molecules23010047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23010047</ArticleId><ArticleId IdType="pmc">PMC5943960</ArticleId><ArticleId IdType="pubmed">29295564</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes M. F.; Ivert P.; Hoeber J.; Han Y.; Feiler A.; Zhou C.; Pankratova S.; Shoshan-Barmatz V.; Israelson A.; Kozlova E. N. Empty Mesoporous Silica Particles Significantly Delay Disease Progression and Extend Survival in a Mouse Model of ALS. Sci. Rep. 2020, 10, 2067510.1038/s41598-020-77578-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77578-x</ArticleId><ArticleId IdType="pmc">PMC7691331</ArticleId><ArticleId IdType="pubmed">33244084</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D.; Lin B.; Shao W.; Zhu Z.; Ji T.; Yang C. In Vitro and in Vivo Studies on the Transport of PEGylated Silica Nanoparticles across the Blood&#x2013;Brain Barrier. ACS Appl. Mater. Interfaces 2014, 6, 2131&#x2013;2136. 10.1021/am405219u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/am405219u</ArticleId><ArticleId IdType="pubmed">24417514</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun G.; Zeng S.; Liu X.; Shi H.; Zhang R.; Wang B.; Zhou C.; Yu T. Synthesis and Characterization of a Silica-Based Drug Delivery System for Spinal Cord Injury Therapy. Nano&#x2013;Micro Lett. 2019, 11, 23.10.1007/s40820-019-0252-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40820-019-0252-6</ArticleId><ArticleId IdType="pmc">PMC7770885</ArticleId><ArticleId IdType="pubmed">34137964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.; Trewyn B. G.; Slowing I. I.; Lin V. S.-Y. Mesoporous Silica Nanoparticle-Based Double Drug Delivery System for Glucose-Responsive Controlled Release of Insulin and Cyclic AMP. J. Am. Chem. Soc. 2009, 131, 8398&#x2013;8400. 10.1021/ja901831u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja901831u</ArticleId><ArticleId IdType="pubmed">19476380</ArticleId></ArticleIdList></Reference><Reference><Citation>Paredes K. O.; D&#xed;az-Garc&#xed;a D.; Garc&#xed;a-Almod&#xf3;var V.; Lozano Chamizo L.; Marciello M.; D&#xed;az-S&#xe1;nchez M.; Prashar S.; G&#xf3;mez-Ruiz S.; Filice M. Multifunctional Silica-Based Nanoparticles with Controlled Release of Organotin Metallodrug for Targeted Theranosis of Breast Cancer. Cancers 2020, 12, 187.10.3390/cancers12010187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12010187</ArticleId><ArticleId IdType="pmc">PMC7017138</ArticleId><ArticleId IdType="pubmed">31940937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I.; Bell S.; Cairns N. J.; Miller T. M.; Baloh R. H. TDP-43 Mutant Transgenic Mice Develop Features of ALS and Frontotemporal Lobar Degeneration. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 18809&#x2013;18814. 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner P. V.; Brabb T.; Pekow C.; Vasbinder M. A. Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider. J. Am. Assoc. Lab. Anim. Sci. 2011, 50, 600&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189662</ArticleId><ArticleId IdType="pubmed">22330705</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks S. P.; Dunnett S. B. Tests to Assess Motor Phenotype in Mice: A User&#x2019;s Guide. Nat. Rev. Neurosci. 2009, 10, 519&#x2013;529. 10.1038/nrn2652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2652</ArticleId><ArticleId IdType="pubmed">19513088</ArticleId></ArticleIdList></Reference><Reference><Citation>Miana-Mena F. J.; Mu&#xf1;oz M. J.; Yag&#xfc;e G.; Mendez M.; Moreno M.; Ciriza J.; Zaragoza P.; Osta R. Optimal Methods to Characterize the G93A Mouse Model of ALS. Amyotrophic Lateral Scler. 2005, 6, 55&#x2013;62. 10.1080/14660820510026162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510026162</ArticleId><ArticleId IdType="pubmed">16036427</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang T. N. T.; Lim N. K. H.; Grubman A.; Li Q.-X.; Volitakis I.; White A. R.; Crouch P. J. Increased Metal Content in the TDP-43(A315T) Transgenic Mouse Model of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Front. Aging Neurosci. 2014, 6, 15.10.3389/fnagi.2014.00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2014.00015</ArticleId><ArticleId IdType="pmc">PMC3920072</ArticleId><ArticleId IdType="pubmed">24575040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandillo S.; Tucci V.; H&#xf6;lter S. M.; Meziane H.; Banchaabouchi M. A.; Kallnik M.; Lad H. V.; Nolan P. M.; Ouagazzal A.-M.; Coghill E. L.; Gale K.; Golini E.; Jacquot S.; Krezel W.; Parker A.; Riet F.; Schneider I.; Marazziti D.; Auwerx J.; Brown S. D. M.; Chambon P.; Rosenthal N.; Tocchini-Valentini G.; Wurst W. Reliability, Robustness, and Reproducibility in Mouse Behavioral Phenotyping: A Cross-Laboratory Study. Physiol. Genomics 2008, 34, 243&#x2013;255. 10.1152/physiolgenomics.90207.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.90207.2008</ArticleId><ArticleId IdType="pmc">PMC2519962</ArticleId><ArticleId IdType="pubmed">18505770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F.; Basinski M. B.; Beals J. M.; Briggs S. L.; Churgay L. M.; Clawson D. K.; DiMarchi R. D.; Furman T. C.; Hale J. E.; Hsiung H. M.; Schoner B. E.; Smith D. P.; Zhang X. Y.; Wery J.-P.; Schevitz R. W. Crystal Structure of the Obese Protein Ieptin-E100. Nature 1997, 387, 206&#x2013;209. 10.1038/387206a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/387206a0</ArticleId><ArticleId IdType="pubmed">9144295</ArticleId></ArticleIdList></Reference><Reference><Citation>Thommes M.; Kaneko K.; Neimark A. V.; Olivier J. P.; Rodriguez-Reinoso F.; Rouquerol J.; Sing K. S. W. Physisorption of Gases, with Special Reference to the Evaluation of Surface Area and Pore Size Distribution (IUPAC Technical Report). Pure Appl. Chem. 2015, 87, 1051&#x2013;1069. 10.1515/pac-2014-1117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/pac-2014-1117</ArticleId></ArticleIdList></Reference><Reference><Citation>Attia A. K.; Ibrahim M. M.; El-ries M. A.-N. Thermal Analysis of Some Antidiabetic Pharmaceutical Compounds. Adv. Pharm. Bull. 2013, 3, 419&#x2013;424. 10.5681/apb.2013.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.5681/apb.2013.067</ArticleId><ArticleId IdType="pmc">PMC3848208</ArticleId><ArticleId IdType="pubmed">24312870</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens T. W.; Basinski M.; Bristow P. K.; Bue-Valleskey J. M.; Burgett S. G.; Craft L.; Hale J.; Hoffmann J.; Hsiung H. M.; Kriauciunas A.; MacKellar W.; Rosteck P. R.; Schoner B.; Smith D.; Tinsley F. C.; Zhang X.-Y.; Heiman M. The Role of Neuropeptide Y in the Antiobesity Action of the Obese Gene Product. Nature 1995, 377, 530&#x2013;532. 10.1038/377530a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/377530a0</ArticleId><ArticleId IdType="pubmed">7566151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T.; Bogdanik L. P.; Tassinari V. R.; Kidd J. D.; Moreno A. J.; Davis C.; Osborne M.; Austin A.; Vieira F. G.; Lutz C.; Perrin S. C57BL/6J Congenic Prp-TDP43A315T Mice Develop Progressive Neurodegeneration in the Myenteric Plexus of the Colon without Exhibiting Key Features of ALS. Brain Res. 2014, 1584, 59&#x2013;72. 10.1016/j.brainres.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.10.013</ArticleId><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili M. A.; Panahi M.; Yadav S.; Hennings L.; Kiaei M. Premature Death of TDP-43 (A315T) Transgenic Mice Due to Gastrointestinal Complications Prior to Development of Full Neurological Symptoms of Amyotrophic Lateral Sclerosis. Int. J. Exp. Pathol. 2013, 94, 56&#x2013;64. 10.1111/iep.12006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12006</ArticleId><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z.; Xing R.; Liu S.; Zhong Z.; Ji X.; Wang L.; Li P. Antifungal Properties of Schiff Bases of Chitosan, N-Substituted Chitosan and Quaternized Chitosan. Carbohydr. Res. 2007, 342, 1329&#x2013;1332. 10.1016/j.carres.2007.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carres.2007.04.006</ArticleId><ArticleId IdType="pubmed">17485075</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina D. X.; Orr M. E.; Oddo S. Accumulation of C-Terminal Fragments of Transactive Response DNA-Binding Protein 43 Leads to Synaptic Loss and Cognitive Deficits in Human TDP-43 Transgenic Mice. Neurobiol. Aging 2014, 35, 79&#x2013;87. 10.1016/j.neurobiolaging.2013.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.006</ArticleId><ArticleId IdType="pubmed">23954172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A.; Ferrer-Donato A.; Cabrera-Pinto M.; Sese&#xf1;a S.; Fern&#xe1;ndez P.; Aranda A.; Fernandez-Martos C. M.. Effect of Ozone Exposure on Amyotrophic Lateral Sclerosis (ALS) Pathology Using a Mice Model of TDP-43 Proteinopathy, 2021. 10.1101/2021.02.12.430915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.12.430915</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>